Table 6 Expected Value of Perfect Information for Parameters
From: Cost-utility analysis of antihypertensive medications in Nigeria: a decision analysis
Parameter | Population EVPPI ($) | Population EVPI ($) |
|---|---|---|
Low Risk | Â | 27,076,912 |
Relative Risk of Thiazide | Â | Â |
Stroke | - | Â |
CHD | - | Â |
Death | - | Â |
Utility | Â | Â |
Non-symptomatic | 5,576 | Â |
Stroke | 2,938 | Â |
CHD | 5,006 | Â |
Cost | Â | Â |
Stroke Hospitalization | 16,518 | Â |
CHD Hospitalization | 14,984 | Â |
Stroke Manage | - | Â |
Yearly Cost Thiazide | 178 | Â |
Moderate Risk | Â | 73,353,965 |
Relative Risk of Thiazide | Â | Â |
Stroke | 3,093,981 | Â |
CHD | 2,648,842 | Â |
Death | 7,221,002 | Â |
Utility | Â | Â |
Non-symptomatic | 2,092,005 | Â |
Stroke | 3,003,524 | Â |
CHD | 2,303,848 | Â |
Cost | Â | Â |
Stroke Hospitalization | 1,224,642 | Â |
CHD Hospitalization | 1,781,143 | Â |
Stroke Manage | 2,392,084 | Â |
Yearly Cost Thiazide | 4,126,641 | Â |
High Risk | Â | 26,667,500 |
Relative Risk of Thiazide | Â | Â |
Stroke | 9,901,387 | Â |
CHD | 5,441,116 | Â |
Death | 646,992 | Â |
Utility | Â | Â |
Non-symptomatic | 1,137,622 | Â |
Stroke | 2,005,656 | Â |
CHD | 1,336,286 | Â |
Cost | Â | Â |
Stroke Hospitalization | 1,378,708 | Â |
CHD Hospitalization | 2,908,565 | Â |
Stroke Manage | 660,668 | Â |
Yearly Cost Thiazide | 437,657 | Â |